enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California. Show more

Location: 70 Doppler, Irvine, CA, 92618, United States | Website: https://www.envveno.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

86.61M

52 Wk Range

$2.03 - $5.70

Previous Close

$4.58

Open

$4.56

Volume

282,988

Day Range

$4.33 - $4.68

Enterprise Value

52.35M

Cash

35.14M

Avg Qtr Burn

-4.279M

Insider Ownership

0.84%

Institutional Own.

20.57%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date